Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of HyperHES infusion speed on systemic hemodynamics in septic or hemorrhagic shock
2007-001475-11Phase 3Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- May 2007
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HyperHAES in septic shock, hemorrhagic shock and Hypotensive shock (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Mean arterial pressure change during and after HyperHES administration. Started May 2007; status: active.
02
Drugs
HyperHAES
03
Conditions
septic shockhemorrhagic shockHypotensive shock
Beyond the preview
Go deeper on 2007-001475-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001475-11.